vs

Side-by-side financial comparison of GEN Restaurant Group, Inc. (GENK) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.

RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $49.7M, roughly 1.2× GEN Restaurant Group, Inc.). GEN Restaurant Group, Inc. runs the higher net margin — -3.8% vs -83.0%, a 79.2% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -9.0%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -1.0%).

Gen Korean BBQ is an American chain of all-you-can-eat Korean barbecue restaurants mainly concentrated around the Western U.S. It opened in 2011, and has since grown to 43 locations as of 2024.

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

GENK vs RYTM — Head-to-Head

Bigger by revenue
RYTM
RYTM
1.2× larger
RYTM
$57.3M
$49.7M
GENK
Growing faster (revenue YoY)
RYTM
RYTM
+45.9% gap
RYTM
36.9%
-9.0%
GENK
Higher net margin
GENK
GENK
79.2% more per $
GENK
-3.8%
-83.0%
RYTM
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
48.5%
-1.0%
GENK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GENK
GENK
RYTM
RYTM
Revenue
$49.7M
$57.3M
Net Profit
$-1.9M
$-47.5M
Gross Margin
91.6%
Operating Margin
-24.5%
-82.2%
Net Margin
-3.8%
-83.0%
Revenue YoY
-9.0%
36.9%
Net Profit YoY
-821.4%
-9.6%
EPS (diluted)
$-0.37
$-0.73

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GENK
GENK
RYTM
RYTM
Q4 25
$49.7M
$57.3M
Q3 25
$50.4M
$51.3M
Q2 25
$55.0M
$48.5M
Q1 25
$57.3M
$32.7M
Q4 24
$54.7M
$41.8M
Q3 24
$49.1M
$33.3M
Q2 24
$53.9M
$29.1M
Q1 24
$50.8M
$26.0M
Net Profit
GENK
GENK
RYTM
RYTM
Q4 25
$-1.9M
$-47.5M
Q3 25
$-566.0K
$-52.9M
Q2 25
$-261.0K
$-46.6M
Q1 25
$-301.0K
$-49.5M
Q4 24
$-206.0K
$-43.3M
Q3 24
$25.0K
$-43.6M
Q2 24
$277.0K
$-32.3M
Q1 24
$496.0K
$-141.4M
Gross Margin
GENK
GENK
RYTM
RYTM
Q4 25
91.6%
Q3 25
89.3%
Q2 25
88.6%
Q1 25
88.8%
Q4 24
90.9%
Q3 24
88.5%
Q2 24
89.9%
Q1 24
89.2%
Operating Margin
GENK
GENK
RYTM
RYTM
Q4 25
-24.5%
-82.2%
Q3 25
-7.4%
-102.6%
Q2 25
-3.4%
-93.4%
Q1 25
-3.8%
-143.7%
Q4 24
-2.4%
-98.6%
Q3 24
0.2%
-132.0%
Q2 24
3.0%
-139.2%
Q1 24
0.2%
-538.7%
Net Margin
GENK
GENK
RYTM
RYTM
Q4 25
-3.8%
-83.0%
Q3 25
-1.1%
-103.1%
Q2 25
-0.5%
-96.1%
Q1 25
-0.5%
-151.4%
Q4 24
-0.4%
-103.6%
Q3 24
0.1%
-131.2%
Q2 24
0.5%
-110.9%
Q1 24
1.0%
-544.4%
EPS (diluted)
GENK
GENK
RYTM
RYTM
Q4 25
$-0.37
$-0.73
Q3 25
$-0.11
$-0.82
Q2 25
$-0.05
$-0.75
Q1 25
$-0.06
$-0.81
Q4 24
$-0.05
$-0.71
Q3 24
$0.01
$-0.73
Q2 24
$0.06
$-0.55
Q1 24
$0.11
$-2.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GENK
GENK
RYTM
RYTM
Cash + ST InvestmentsLiquidity on hand
$2.8M
$388.9M
Total DebtLower is stronger
$13.6M
Stockholders' EquityBook value
$26.5M
$139.1M
Total Assets
$259.9M
$480.2M
Debt / EquityLower = less leverage
0.51×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GENK
GENK
RYTM
RYTM
Q4 25
$2.8M
$388.9M
Q3 25
$4.8M
$416.1M
Q2 25
$9.6M
$291.0M
Q1 25
$15.4M
$314.5M
Q4 24
$23.7M
$320.6M
Q3 24
$22.1M
$298.4M
Q2 24
$29.2M
$319.1M
Q1 24
$28.1M
$201.2M
Total Debt
GENK
GENK
RYTM
RYTM
Q4 25
$13.6M
Q3 25
$10.8M
Q2 25
$7.8M
Q1 25
$6.5M
Q4 24
$6.9M
Q3 24
$7.2M
Q2 24
$7.6M
Q1 24
$7.7M
Stockholders' Equity
GENK
GENK
RYTM
RYTM
Q4 25
$26.5M
$139.1M
Q3 25
$38.1M
$148.8M
Q2 25
$41.0M
$-11.9M
Q1 25
$42.8M
$18.9M
Q4 24
$44.1M
$21.7M
Q3 24
$46.5M
$11.2M
Q2 24
$45.9M
$39.3M
Q1 24
$40.4M
$61.6M
Total Assets
GENK
GENK
RYTM
RYTM
Q4 25
$259.9M
$480.2M
Q3 25
$245.5M
$506.9M
Q2 25
$246.3M
$372.7M
Q1 25
$232.4M
$386.7M
Q4 24
$240.4M
$392.3M
Q3 24
$225.7M
$363.6M
Q2 24
$218.8M
$381.8M
Q1 24
$214.5M
$258.7M
Debt / Equity
GENK
GENK
RYTM
RYTM
Q4 25
0.51×
Q3 25
0.28×
Q2 25
0.19×
Q1 25
0.15×
Q4 24
0.16×
Q3 24
0.16×
Q2 24
0.17×
Q1 24
0.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GENK
GENK
RYTM
RYTM
Operating Cash FlowLast quarter
$-426.0K
$-25.4M
Free Cash FlowOCF − Capex
$-5.6M
FCF MarginFCF / Revenue
-11.3%
Capex IntensityCapex / Revenue
10.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-24.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GENK
GENK
RYTM
RYTM
Q4 25
$-426.0K
$-25.4M
Q3 25
$-1.6M
$-26.6M
Q2 25
$3.3M
$-23.3M
Q1 25
$2.2M
$-40.4M
Q4 24
$7.3M
$-18.8M
Q3 24
$1.4M
$-25.2M
Q2 24
$5.6M
$-29.1M
Q1 24
$3.5M
$-40.7M
Free Cash Flow
GENK
GENK
RYTM
RYTM
Q4 25
$-5.6M
Q3 25
$-7.7M
Q2 25
$-6.3M
Q1 25
$-4.7M
Q4 24
$165.0K
Q3 24
$-6.8M
Q2 24
$1.2M
Q1 24
$-586.0K
FCF Margin
GENK
GENK
RYTM
RYTM
Q4 25
-11.3%
Q3 25
-15.3%
Q2 25
-11.5%
Q1 25
-8.2%
Q4 24
0.3%
Q3 24
-13.9%
Q2 24
2.3%
Q1 24
-1.2%
Capex Intensity
GENK
GENK
RYTM
RYTM
Q4 25
10.5%
Q3 25
12.0%
Q2 25
17.5%
Q1 25
11.9%
Q4 24
13.1%
Q3 24
16.9%
Q2 24
8.0%
Q1 24
8.1%
Cash Conversion
GENK
GENK
RYTM
RYTM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
57.96×
Q2 24
20.06×
Q1 24
7.08×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons